Rockfish Bio focuses on the development of senolytic therapies for age-related diseases.

Rockfish Bio

red-stars.com data AG offers B2B software solutions and innovative life sciences technologies, creating scalable, mission-critical products. Data is at the core of everything the company does, whether it’s optimizing business performance or enabling scientific breakthroughs.

red-stars.com data AG

Rockfish Bio | 692 followers on LinkedIn. Improving the quality of life by promoting healthy aging. | Rockfish Bio is a biotech company centred on the development of senolytic compounds based on a newly discovered target pathway. Our target pathway was successfully tested in 7 different cell types with a therapeutic index of up to 700. Our lead candidate RFB01016 was able to restore neuromuscular functions and massively extend the health and life span (+40 % median survival time after start of treatment) in naturally aged mice.

Biotechnology of Regeneration and Aging

Johannes Grillari

CEO for InnoFly BioCenter GmbH & Director DMPK at Rockfish Bio AG

Dirk B. Strickmann

CSO/COO of Rockfish Bio AG

Ingo Lämmermann

Scientist

Viviane Fleischhacker

🧟♂️ Auf der Jagd nach Zombiezellen 🧟♂️ - Noch ist sie ein Traum: die Unsterblichkeit. Doch mittlerweile arbeiten zahlreiche Start-ups daran, dem irdischen Dasein zumindest ein paar weitere Jährchen zu spendieren. Darunter auch das junge Wiener Unternehmen Rockfish Bio , das sich vor allem das gesunde Altern auf die Fahne geschrieben hat. Was das mit dem Fettsäurestoffwechsel und Zombiezellen zu tun hat, erklärt Mitgründer Ingo Lämmermann in meinem Artikel im Das Laborjournal . https://lnkd.in/eUK2k588

Tobias Ludwig

🔬 Innovative Ansätze für gesundes Altern: Die BOKU University hat eine zentrale Rolle bei der Erstellung eines neuen internationalen Konsenspapiers gespielt, das die Bedeutung seneszenter Zellen im Alterungsprozess beleuchtet. Diese Zellen, die infolge zellulären Stresses entstehen und chronische Entzündungen begünstigen, stehen im Zentrum innovativer therapeutischer Ansätze zur Bekämpfung altersbedingter Krankheiten. Unter der Leitung von Johannes Grillari , vom BOKU-Institut für Molekulare Biotechnologie, haben österreichische und internationale Expert*innen gemeinsam die MICSE-Leitlinien entwickelt. Diese Leitlinien definieren standardisierte Marker und Methoden zur Untersuchung seneszenter Zellen. Die Veröffentlichung der Leitlinien in der renommierten Fachzeitschrift „Cell“ stellt einen wichtigen Meilenstein auf dem Weg zur klinischen Anwendung dar und zielt darauf ab, die Gesundheitsspanne der Menschen deutlich zu verlängern. Das BOKU-Spin-off Rockfish Bio plant, diese vielversprechenden Forschungsergebnisse in konkrete therapeutische Ansätze zu überführen. ℹ️ https://lnkd.in/guN9-DJD

University of Natural Resources and Life Sciences, Vienna (BOKU)

Dear Olga, thank you for your comprehensive summary of our talk! It is great to be here in Berlin and to be able to present our newest data on the rejuvenating effect of our lead compound in front of such a well educated audience.

Meet us at the Rejuvenation Startup Summit 2024! I am happy to announce that our CEO Otto Kanzler was invited to present our company at this exciting event, where investors can meet the leaders of the rejuvenation biotech industry. https://lnkd.in/gJYzViw7

Read more about our latest successes and plans in this year's startupreport.at/get23 It is inspiring to read about the progress, funding successes and innovations of so many Austrian startups. Thanks Dr. Florian Kandler and the Startup Report team for promoting entrepreneurship and innovation this way. We are glad to be part of this initiative!

Could "old" become the new "sexy"? Our senolytic lead compound improves not only the health and life span but also the looks of our mice. If you are interested in joining our series A funding, please get in touch with us!

Excellent data from PoC study with our senolytic lead molecule RFB01016! Our newest data shows a massive extension of health span (frailty index) and life span (+40 % of median survival time), as well as improvements in neuromuscular function and reduction of senescent cells in several tissues (kidney, liver, brain, spleen, fat, ...). We are currently seeking funding, so don't miss this opportunity and get in touch with us!

Metric
Company Name	Rockfish Bio	red-stars.com data AG
Symbol
MSH ID	COM:ROCKFISHBIO	COM:RED-STARS
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Technology
Industry	Biotechnology	Software and Life Sciences
Country	AT	AT
Stage
Employee Count
Website	rockfishbio.com	red-stars.com
LinkedIn	rockfish-bio	red-stars-com
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	106
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ROCK

COM:ROCKFISHBIO

Rockfish Bio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue